The KEYS trial (2022) studied the addition of pembrolizumab (PD-1 inhibitor) to concurrent chemoradiation in locally advanced cervical cancer. What was the primary endpoint result?
- A Pembrolizumab significantly improved overall survival as the primary endpoint
- B Pembrolizumab significantly improved progression-free survival (PFS) as the primary endpoint ✓
- C Pembrolizumab showed no benefit in PFS or OS
- D Pembrolizumab improved complete response rate but not survival
Correct answer: B. Pembrolizumab significantly improved progression-free survival (PFS) as the primary endpoint
Explanation
The KEYNOTE-A18 (ENGOT-cx11/GOG-3047/KEYS) trial demonstrated that adding pembrolizumab to concurrent cisplatin-based chemoradiation significantly improved progression-free survival (PFS) as the primary endpoint in locally advanced cervical cancer (Stages IB2–IVA). Overall survival data also showed benefit at interim analysis. This trial supports pembrolizumab as a new standard addition to chemoradiation for locally advanced disease.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.